The medial prefrontal cortex (mPFC) is a critical brain region involved in executive function, decision-making, emotional regulation, and social cognition. Located in the anterior portion of the frontal lobe, the mPFC comprises several subregions including the anterior cingulate cortex (ACC), prelimbic cortex, infralimbic cortex, and medial orbital cortex. These subregions form dense reciprocal connections with the hippocampus, amygdala, thalamus, and brainstem nuclei, creating a hub for integrating cognitive and emotional information[1].
The mPFC is subdivided into dorsal and ventral regions with distinct connectivity patterns. The dorsal mPFC (including ACC and prelimbic cortex) projects to the parietal cortex and dorsal striatum, mediating executive control and working memory. The ventral mPFC (including infralimbic cortex) connects to the amygdala, hippocampus, and hypothalamus, regulating emotional responses and fear conditioning[2].
Key neurotransmitter systems in the mPFC include glutamate (pyramidal neurons), GABA (interneurons), dopamine (from ventral tegmental area), and serotonin (from dorsal raphe). Pyramidal neurons express NMDA and AMPA receptors, while interneurons include parvalbumin-positive, somatostatin-positive, and cholecystokinin-positive subtypes[3].
The mPFC shows early vulnerability in Alzheimer's disease (AD), with hypometabolism and atrophy detectable in mild cognitive impairment (MCI) stages. Neurofibrillary tau pathology spreads to the mPFC in Braak stages IV-VI, disrupting synaptic function and leading to executive dysfunction[4]. Studies using PET imaging show that mPFC glucose hypometabolism correlates with deficits in working memory and task-switching in AD patients[5].
In Parkinson's disease (PD), mPFC dysfunction contributes to executive impairment and levodopa-induced behavioral side effects. Dopaminergic denervation in the mPFC alters working memory and decision-making processes. Deep brain stimulation of the subthalamic nucleus can modulate mPFC activity, improving cognitive symptoms in some patients[6].
Frontotemporal dementia (FTD), particularly the behavioral variant (bvFTD), shows prominent mPFC degeneration. Patients exhibit early loss of empathy, social conduct, and executive function due to mPFC atrophy and tau/TDP-43 pathology. The anterior cingulate cortex shows reduced thickness in FTD, correlating with apathy and disinhibition[7].
Richardson's syndrome (PSP) features early midbrain and pontine pathology, but mPFC involvement contributes to frontal executive deficits. PSP patients show impaired task-switching and planning that correlates with prefrontal connectivity disruption[8].
mPFC pyramidal neurons express calcium-binding proteins (calbindin, calretinin) and transcription factors (CTIP2, SATB2) that define their subtype identity. These neurons show differential vulnerability to neurodegenerative processes based on their molecular profile and connectivity[9].
Understanding mPFC dysfunction in neurodegeneration guides therapeutic development. Non-invasive brain stimulation (tDCS, rTMS) targeting the mPFC shows promise for improving executive function in AD and PD. Cholinergic agents that enhance prefrontal neurotransmission may benefit memory and attention in AD[10].
Funahashi et al. Prefrontal cortex and working memory (2023). Nature Reviews Neuroscience. 2023. ↩︎
Price et al. Prefrontal cortex connectivity (2022). Cerebral Cortex. 2022. ↩︎
Goncharova et al. Prefrontal interneuron diversity (2021). Journal of Neuroscience. 2021. ↩︎
Braak et al. Staging of Alzheimer pathology (2020). Acta Neuropathologica. 2020. ↩︎
Mosconi et al. mPFC hypometabolism in MCI (2021). Journal of Alzheimer's Disease. 2021. ↩︎
Narayanan et al. Prefrontal dysfunction in PD (2022). Brain. 2022. ↩︎
Rascovsky et al. bvFTD diagnostic criteria (2021). Brain. 2021. ↩︎
-PSP executive dysfunction (2023). Neurology. 2023. ↩︎
Bhatt et al. mPFC neuronal subtypes (2022). Cell Reports. 2022. ↩︎
Hsu et al. Non-invasive stimulation for AD (2023). Alzheimer's & Dementia. 2023. ↩︎